PEGylated Protein Therapeutics Market is estimated to flourish at a compound annual growth rate (CAGR) of 6.9% by 2025
A Comprehensive research study conducted by KD Market Insights on " PEGylated Protein Therapeutics Market by Product Type (Colony Stimulating Factor, Interferon, Erythropoietin (EPO), Recombinant Factor VIII, Monoclonal Antibody, Enzyme, and Others) By Application (Cancer, Autoimmune Disease, Hepatitis, Multiple Sclerosis, Hemophilia, Gastrointestinal Disorder, and Others) By Sales Channel (Hospital Pharmacy, Online Provider, and Retail Pharmacy) - Global Opportunity Analysis and Industry Forecast, 2018-2025" report offers extensive and highly detailed historical, current and future market trends in the global and regional/market. The PEGylated Protein Therapeutics Market report includes market size, growth drivers, barriers, opportunities, trends and other information which helps to find new opportunities in this market for the growth of the business through new technologies and developments.
The global PEGylated protein therapeutics market was valued at $10,388 million in 2017, and is estimated to reach at $17,813 million by 2025, registering a CAGR of 6.9% from 2018 to 2025. The factors that propel the PEGylated protein therapeutics market growth include high prevalence of chronic diseases, such as cancer, kidney diseases, and rheumatoid arthritis. In addition, growth in the biologics sector with an increase in R&D expenditure of pharmaceutical and biopharmaceutical companies boosts the market. Furthermore, increase in government funding and grants for research activities enhance opportunities for the growth of the market. However, high price, and expected launch of generic drugs can hinder the growth.
Request for Sample@ https://www.kdmarketinsights.com/sample/4194
The global PEGylated protein therapeutics market is segmented based on product type, application, sales channel, and region. According to the product type, the market is classified into colony stimulating factor, interferon, erythropoietin, recombinant factor VIII, monoclonal antibody, enzyme, and others. Based on application, the market is categorized into cancer, autoimmune disease, hepatitis, multiple sclerosis, hemophilia, gastrointestinal disorder, and others. According to the sales channel, it is segmented into hospital pharmacy, online provider, and retail pharmacy. Based on region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Key players profiled in the report include Amgen Inc., AstraZeneca PLC, Biogen, Inc., F. Hoffmann-La Roche Ltd. (Genentech, Inc.,), Horizon Pharma plc., Leadiant Biosciences S.p.A., Merck & Co., Inc. (Schering-Plough Corporation), Pfizer Inc., Shire plc (Baxalta), and UCB S.A.
KEY BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers a quantitative analysis from 2017 to 2025, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
- A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS
By Product Type
- Colony Stimulating Factor
- Erythropoietin (EPO)
- Recombinant Factor VIII
- Monoclonal Antibody
By Application Type
- Autoimmune Disease
- Multiple Sclerosis
- Gastrointestinal Disorder
By Sales Channel
- Hospital Pharmacy
- Online Provider
- Retail Pharmacy
- Rest of Europe
- South Korea
- Rest of Asia-Pacific
- Saudi Arabia
- South Africa
- Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
- Amgen Inc.
- AstraZeneca PLC
- Biogen, Inc.
- F. Hoffmann-La Roche Ltd. (Genentech, Inc.,),
- Horizon Pharma plc.
- Leadiant Biosciences S.p.A.
- Merck & Co., Inc. (Schering-Plough Corporation)
- Pfizer Inc.
- Shire plc (Baxalta)
- UCB S.A.
Browse Full Report with TOC @ https://www.kdmarketinsights.com/product/pegylated-protein-therapeutics-market-amr
Table of Contents:
CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Benefits for Stakeholders
1.3. Key Market Segments
1.3.1. List of key players profiled in the report
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key Findings of the Study
2.2. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top investment pockets
3.3. Top Player Positioning, 2017
3.4. Clinical Trials
3.5. Market Dynamics
126.96.36.199. Strong presence of pipeline drugs
188.8.131.52. Advantages offered by PEGylation
184.108.40.206. Rise in the prevalence of chronic diseases
220.127.116.11. High costs associated with drug development
18.104.22.168. Expected Launch of generic drugs
22.214.171.124. Untapped emerging economies
126.96.36.199. Growth in adoption of PEGylated protein therapeutics
3.5.4. Impact Analyses
CHAPTER 4: PEGYLATED PROTEIN THERAPEUTICS MARKET, BY PRODUCT TYPE
4.1.1. Market size and forecast
4.2. Colony Stimulating Factor
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast
4.4. Erythropoietin (EPO)
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast
4.5. Recombinant Factor VIII
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast
4.6. Monoclonal Antibody
4.6.1. Key market trends, growth factors, and opportunities
4.6.2. Market size and forecast
4.7.1. Key market trends, growth factors, and opportunities
4.7.2. Market size and forecast
4.8. Other PEGylated Protein Therapeutics
4.8.1. Key market trends, growth factors, and opportunities
4.8.2. Market size and forecast
CHAPTER 5: PEGYLATED PROTEIN THERAPEUTICS MARKET, BY APPLICATION
5.1.1. Market size and forecast
5.2.1. Market size and forecast
5.3. Autoimmune Disease
5.3.1. Market size and forecast
5.4.1. Market size and forecast
5.5. Multiple Sclerosis
5.5.1. Market size and forecast
5.6.1. Market size and forecast
5.7. Gastrointestinal Disorders
5.7.1. Market size and forecast
5.8. Other Applications
5.8.1. Market size and forecast
CHAPTER 6: PEGYLATED PROTEIN THERAPEUTICS MARKET, BY SALES CHANNEL
6.1.1. Market size and forecast
6.2. Hospital Pharmacy
6.2.1. Market size and forecast, by region
6.3. Online Providers
6.3.1. Market size and forecast, by region
6.4. Retail Pharmacy
6.4.1. Market size and forecast, by region
Check for Discount @ https://www.kdmarketinsights.com/discount/4194
KD Market Insights is one of the leading providers of market intelligence products and services. We offer reports on over 10+ industries and update our collection daily which helps our clients to access database of expert market insights on global industries, companies, products, and trends. Our in-house research experts have a wealth of knowledge in their respective domains. With KD Market Research, you always have the choice of getting customized report free of cost (up to 10%). Our support team will help you customize the report and scope as per your business needs. This ensures that you are making the right purchase decision.
Our clients list includes various Fortune 500 companies and leading advisory firms.
KD Market Insights
90 State Street, Albany,
New York, USA 12207
+1 (518) 300-1215
Read More News: https://marketresearch531064260.wordpress.com/